Compare · Health Care
Intuitive Surgical vs. Stryker: how they make money
The same facts for both companies, in the same order, from each company's own page and filings. It is not a ranking.
How they differ
In FY2025, Stryker's revenue of $25.1B was about 2.5 times Intuitive Surgical's $10.1B (Cityfort calculation: one divided by the other).
Intuitive Surgical's largest segment is Instruments and accessories, 59.8% of revenue in FY2025; Stryker's largest segment is MedSurg and Neurotechnology, 54.5% of revenue in FY2025.
United States brought in 68.0% of Intuitive Surgical's revenue in FY2025; United States brought in 75.7% of Stryker's revenue in FY2025.
Intuitive Surgical's largest payer group is U.S. hospitals, 68.0% of revenue (FY2025); Stryker's largest payer group is Hospitals and doctors in the US, 75.7% of revenue (FY2025).
Neither page lists the other among its competitors.
Each company in 5 points
Intuitive Surgical
1 · What it sells
Intuitive Surgical sells da Vinci and Ion surgical robots and the instruments used in each operation: instruments and accessories brought in $6.02 billion of FY2025 revenue of $10.06 billion, systems $2.47 billion and services $1.57 billion.
Sources and detail on the Intuitive Surgical page2 · Who pays it
Hospitals are Intuitive's customers, and U.S. customers made up 68% of FY2025 revenue while customers outside the U.S. made up 32%.
Sources and detail on the Intuitive Surgical page3 · What it keeps from $100
Of every $100 that came in during FY2025, Intuitive kept $27.4 as net income, while operating profit, before $366 million of interest and other income and tax, was $29.3 per $100 of revenue.
Sources and detail on the Intuitive Surgical page4 · Where the operating profit comes from
Intuitive reports one segment and no profit by product: FY2025 operating profit was $2.95 billion, after $3.42 billion of cost of revenue, $2.39 billion of selling and administration and $1.31 billion of research.
Sources and detail on the Intuitive Surgical page5 · The one thing to watch
Worldwide da Vinci procedures grew about 18% in FY2025 and about 14% in Q3 FY2026, while the installed base reached 12,094 systems at Sep 30, 2026.
Sources and detail on the Intuitive Surgical page
Stryker
1 · What it sells
Stryker sells orthopedic implants, surgical and endoscopy equipment, patient care products and the Mako robot, with FY2025 net sales of $25.1 billion, 54.5% from MedSurg and Neurotechnology and 45.5% from Orthopaedics.
Sources and detail on the Stryker page2 · Who pays it
Stryker reports no sales by type of payer and names no large customer; by selling location, customers in the US paid 75.7% of FY2025 net sales and customers outside the US 24.3%.
Sources and detail on the Stryker page3 · What it keeps from $100
Of every $100 that came in during FY2025, Stryker kept $12.8 as net earnings after a 28.1% tax rate, and its operating income was $19.47 per $100 of sales.
Sources and detail on the Stryker page4 · Where the operating profit comes from
In FY2025 Orthopaedics earned 50.6% of Stryker's segment operating income on 45.5% of net sales, and MedSurg and Neurotechnology 49.4% on 54.5%.
Sources and detail on the Stryker page5 · The one thing to watch
Stryker lowered its FY2026 organic sales growth outlook to 6.5% to 7.0% on Oct 29, 2026, from 8.0% to 9.5% in January, and its Q3 FY2026 net earnings of $753 million included a $293 million goodwill impairment.
Sources and detail on the Stryker page
Where each $100 went
Each company's own receipt for its latest full fiscal year, with matching lines in the same order where both have them.
Intuitive Surgical
Where $100 went · FY2025
| Selling, general and administrative | $22.8 |
|---|---|
| Cost of revenue | $32.8 |
| Research and development | $12.6 |
| China joint venture partner's share | $0.2 |
| Income tax | $4.2 |
| Kept as net income | $27.4 |
| Total | $100 |
Cityfort calculation from the FY2025 10-K. Of every $100 that came in during FY2025 (revenue of $10,064.7 million plus $365.9 million of interest and other income): each line = line ÷ $10,430.6 million × 100.
Stryker
Where $100 went · FY2025
| Selling, general and administrative | $34.1 |
|---|---|
| Making the products (cost of sales) | $35.7 |
| Research, development and engineering | $6.4 |
| Amortization and impairments | $3.6 |
| Interest | $2.4 |
| Income tax | $5.0 |
| Kept as net earnings | $12.8 |
| Total | $100 |
Cityfort calculation from the FY2025 10-K. Of every $100 that came in during FY2025 (net sales of $25.1 billion plus $232 million of other income): each line = line ÷ $25.35 billion × 100.
Line items differ because each company groups its costs its own way in its filings. Only on Intuitive Surgical's receipt: Cost of revenue; Research and development; China joint venture partner's share; Kept as net income. Only on Stryker's receipt: Making the products (cost of sales); Research, development and engineering; Amortization and impairments; Interest; Kept as net earnings.
Revenue, net income and free cash flow
Up to five fiscal years for each company, drawn on one shared scale per measure. Amounts in US$ as reported (GAAP).
Revenue
Intuitive Surgical
Stryker
See the numbers
Net income
Intuitive Surgical
Stryker
See the numbers
Free cash flow
Intuitive Surgical
Stryker
See the numbers
Growth and net margin, FY2021 to FY2025
Worked out over the years both pages cover, so the two growth figures use the same span. Net margin is net income as a share of revenue, as on each page.
Intuitive Surgical
- Revenue, per year
- +15.2%
- Net income, per year
- +13.8%
Stryker
- Revenue, per year
- +10.1%
- Net income, per year
- +13.0%
Cityfort calculation: compound growth per year from FY2021 to FY2025 (4 years), from each page's yearly numbers, as reported.
Net margin by year
Latest quarter, against the same quarter a year earlier
Each page's latest quarter as reported; the change is a Cityfort calculation.
Intuitive Surgical
Q3 FY2026, the quarter to Sep 30, 2026, against Q3 FY2025
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $3.0B | $2.5B | +21.7% |
| Net income | $523M | $704M | −25.8% |
Stryker
Q3 FY2026, the quarter to Sep 30, 2026, against Q3 FY2025
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $6.5B | $6.1B | +7.6% |
| Net income | $753M | $859M | −12.3% |
Sources: Intuitive Surgical S11, S8, S10, S5 · Stryker S9, S10, S11, S12, S13, S3
Who pays each company
Intuitive Surgical
- U.S. hospitals · 68.0% of revenueBuy or lease da Vinci and Ion systems, buy instruments for each procedure and pay for service. U.S. revenue was $6.82 billion in FY2025, including $4.20 billion of instruments and accessories.
- Hospitals outside the U.S. · 32.0% of revenueServed directly in parts of Europe, Japan, Korea, India, Taiwan and Canada, through a joint venture in China and through distributors elsewhere. Revenue was $3.25 billion in FY2025.
Stryker
- Hospitals and doctors in the US · 75.7% of revenueDoctors, hospitals and other healthcare facilities buying implants, equipment and disposables, reached mostly through Stryker's own sales teams.
- Hospitals and doctors outside the US · 24.3% of revenueCustomers in Europe, the Middle East and Africa (12.7% of FY2025 net sales), Asia Pacific (8.6%) and Canada and Latin America (3.0%), served by Stryker subsidiaries and by distributors.
Revenue by segment
Intuitive Surgical
FY2025
| Segment | Revenue | Share |
|---|---|---|
| Instruments and accessories | $6.0B | 59.8% |
| Systems | $2.5B | 24.6% |
| Services | $1.6B | 15.6% |
Stryker
FY2025
| Segment | Revenue | Share |
|---|---|---|
| MedSurg and Neurotechnology | $13.7B | 54.5% |
| Orthopaedics | $11.4B | 45.5% |
Where the revenue comes from
Revenue by region, as each company splits it, with the period.
Intuitive Surgical
FY2025
- United States68.0%
- Outside the United States32.0%
Stryker
FY2025
- United States75.7%
- Europe, Middle East and Africa12.7%
- Asia Pacific8.6%
- Canada and Latin America3.0%
Debt and cash
Intuitive Surgical
- Debt
- $0M
- Cash and investments
- $6.8B
On Sep 30, 2026.
At Sep 30, 2026, Intuitive had no borrowings and $6.80 billion of cash and investments, down from $9.03 billion at Dec 31, 2025.
Stryker
- Debt
- $14.9B
- Cash and investments
- $3.3B
On Sep 30, 2026.
Net debt was $11.7 billion at Sep 30, 2026, about 1.9 times FY2025 EBITDA of $6.1 billion (Cityfort calculation from the FY2025 10-K and the Q3 FY2026 10-Q).
Sources: Intuitive Surgical S5, S8, S1 · Stryker S3, S1, S29, S31
Who owns each company
Intuitive Surgical
- One class of shares.
- Officers and directors as a group: 0.6% of shares (as of Dec 31, 2025).
- BlackRock, Inc.: 8.6% (as of Dec 31, 2025).
- Vanguard Capital Management: 7.5% (as of Mar 31, 2026).
Stryker
- One class of shares.
- Officers and directors as a group: 4.6% of shares (as of Feb 28, 2026).
- Vanguard Capital Management LLC: 6.7% (as of Apr 30, 2026).
- BlackRock, Inc.: 6.5% (as of Jan 29, 2024).
- John W. Brown: 5.2% (as of Feb 9, 2021).
- 3 more holders on the Stryker page.
Sources: Intuitive Surgical S16, S5, S26, S24, S23 · Stryker S14, S3, S23
What protects each business
What each page lists as protecting the business from competitors, each with its written reason. These describe business traits, not the share.
Intuitive Surgical
- Installed base and recurring use
11,106 da Vinci systems were installed at Dec 31, 2025, and about 3.15 million da Vinci procedures were done in FY2025, each using Intuitive's instruments.
- Surgeon training and hospital workflow
Surgeons operate from Intuitive's console and can train on its SimNow simulator. System sales generally include five years of service, and service contracts have generally been renewed, the 10-K says.
- Research spending
Research and development was $1.31 billion in FY2025, 13.0% of revenue, and da Vinci 5 placements reached 870 that year.
Stryker
- Direct sales reach
Stryker sells in about 61 countries through its own subsidiaries and distributors, and markets most products directly to doctors and hospitals.
- Broad product range
Nine of Stryker's ten product businesses had FY2025 net sales above $1 billion; the tenth, Spinal Implants, was sold in 2025. The largest, Medical, had $4.20 billion.
- Steady gross profit
Gross profit stayed between $62.8 and $64.1 per $100 of net sales in each year from FY2021 to FY2025.
- Patents
Stryker held about 5,600 US patents and about 9,000 patents outside the US at Dec 31, 2025.
Where growth could come from
Each page's growth drivers. The status compares progress with what the company itself said it would do; it is not a view on the share.
Intuitive Surgical
- More procedures on installed robots · Working: on track against what the company saidda Vinci procedures +14% in Q3 FY2026
- da Vinci 5 · Working: on track against what the company said315 of 546 placements in Q3 FY2026
- Ion lung biopsies · Working: on track against what the company saidIon procedures +31% in Q3 FY2026
- Procedures outside the U.S. · Working: on track against what the company saidAbout +23% in FY2025
- Selling directly in southern Europe · New: recently announcedAbout $533 million, closed Mar 1, 2026
Stryker
- Ortho Tech (Mako robot, power tools) · Working: on track against what the company said+15.8% in Q3 FY2026
- Endoscopy · Working: on track against what the company said+13.9% in Q3 FY2026
- Medical (patient care and emergency equipment) · Working: on track against what the company said+9.7% in Q3 FY2026
- Vascular, including Inari Medical · Mixed: partly on track+8.0% in Q3 FY2026
- Knees and hips · Mixed: partly on trackKnees +1.1%, hips −1.0%, Q3 FY2026
Sources: Intuitive Surgical S1, S8, S9, S10, S12, S5, S19 · Stryker S13, S15, S3
Dividends, buybacks, auditor and credit rating
Dividends per share and buybacks for up to five years, the independent auditor and the latest credit rating, as each page records them.
Intuitive Surgical
- Dividends per shareNo dividends on the page up to FY2025.
- Buybacks
- Dec 31, 2022: Bought back $2.61 billion of shares during FY2022. ($2.6B)
- Dec 31, 2023: Bought 1.7 million shares for $416 million during FY2023. ($416M)
- Dec 31, 2025: Bought 4.8 million shares for $2.30 billion during FY2025. ($2.3B)
- Sep 30, 2026: Bought 11.0 million shares for $4.45 billion, an average of $405.51 a share, in the first nine months of 2026; 7.8 million of them in Q3 FY2026 for $2.94 billion. ($4.4B)
- AuditorPricewaterhouseCoopers LLP, since 2014
- Credit ratingNo public credit rating found.
Stryker
- Dividends per shareFY2021: $2.59 (47.6% of profit) · FY2022: $2.84 (44.6% of profit) · FY2023: $3.05 (36.0% of profit) · FY2024: $3.24 (40.7% of profit) · FY2025: $3.40 (39.6% of profit)
- Buybacks
- Sep 30, 2026: Bought back 3 million shares for $1.0 billion in Q3 FY2026, the first repurchases since at least FY2021. The board added $3.0 billion to the authorization in October 2026, bringing it to $3.03 billion. ($1.0B)
- AuditorErnst & Young LLP, since 1974
- Credit ratingNo public credit rating found.
Sources: Intuitive Surgical S3, S1, S5 · Stryker S1, S2, S3, S13, S14
Risks only one page tracks
Risks whose type the other company's page does not list. Both pages track risks of these types: legal cases, regulation, demand. Every risk is on each company's page.
Intuitive Surgical
- More robot makers entering the field (competition)The FY2025 10-K names 14 companies, including Medtronic and Johnson & Johnson, that have introduced robotic systems or said they plan to. It expects increasing competition in China and says rivals could bring pricing pressure.
Stryker
- Cyber incident hit Q1 FY2026 (technology)A cybersecurity incident found on Mar 11, 2026 disrupted order processing, manufacturing and shipping. Stryker said it had a material impact on Q1 FY2026 results: net sales grew 2.6% and organic growth was 2.4%, against 7.7% to 11.0% in the seven other quarters from Q4 FY2024 to Q3 FY2026. The cost has not been disclosed. A Mar 20, 2026 letter from the outside investigators, Unit 42, filed with an 8-K on Mar 23, 2026, reported that all known signs of the intrusion had been addressed.
- Peripheral Vascular impairment after the Inari deal (execution)Stryker paid $4.81 billion, net of cash acquired, for Inari Medical in February 2025. In Q3 FY2026 it booked a $293 million goodwill impairment on Peripheral Vascular, citing near-term operational and supply constraints and a longer expected path to growth.
- Acquired assets are half of the balance sheet (execution)Goodwill and other intangible assets were $25.0 billion, 52.2% of total assets, at Dec 31, 2025. Impairments cut operating income by $977 million in FY2024 and $170 million in FY2025. The 10-K names acquisitions that do not deliver as a risk.
- Pricing pressure from hospitals and governments (pricing)The 10-K names hospital cost-cutting, provider consolidation, government payers and China's volume-based procurement (bulk tendering) as sources of pressure on prices. US customers paid 75.7% of FY2025 net sales.
Sources: Intuitive Surgical S1 · Stryker S16, S17, S18, S11, S5, S32, S6, S7, S8, S9, S10, S12, S13, S1, S21, S3
Key facts
- How does Intuitive Surgical make money compared with Stryker?
- Intuitive Surgical's revenue by segment in FY2025: Instruments and accessories 59.8%, Systems 24.6%, Services 15.6%. Stryker's revenue by segment in FY2025: MedSurg and Neurotechnology 54.5%, Orthopaedics 45.5%.
- Which is bigger by revenue, Intuitive Surgical or Stryker?
- Intuitive Surgical reported $10.1B of revenue in FY2025, and Stryker reported $25.1B in FY2025.
- How much net income did Intuitive Surgical and Stryker report?
- Intuitive Surgical reported net income of $2.9B in FY2025, and Stryker reported $3.2B in FY2025.
- How much of every $100 did Intuitive Surgical and Stryker keep as net income?
- Intuitive Surgical kept $27.4 of every $100 that came in during FY2025, and Stryker kept $12.8 in FY2025 (Cityfort calculation from each company's annual report).
- How much debt and cash do Intuitive Surgical and Stryker have?
- Intuitive Surgical had $0M of debt and $6.8B of cash and investments on Sep 30, 2026. Stryker had $14.9B of debt and $3.3B of cash and investments on Sep 30, 2026.
- When do Intuitive Surgical's and Stryker's fiscal years end?
- Intuitive Surgical: Fiscal year ends on December 31. Stryker: December 31 (the fiscal year is the calendar year, so Q3 FY2026 is July to September 2026).
Sources: Intuitive Surgical S3, S1, S5, S8 · Stryker S1, S2, S15, S3, S29, S31
Built from each company's page. Intuitive Surgical updated Nov 6, 2026; Stryker updated Nov 6, 2026.
Sources
Intuitive Surgical
- S1Form 10-K, fiscal year 2025 (ended December 31, 2025), Intuitive Surgical, Inc. (SEC EDGAR), Feb 3, 2026
- S3Form 10-K, fiscal year 2023 (ended December 31, 2023), Intuitive Surgical, Inc. (SEC EDGAR), Jan 31, 2024
- S5Form 10-Q, third quarter 2026 (quarter ended September 30, 2026), Intuitive Surgical, Inc. (SEC EDGAR), Oct 21, 2026
- S8Third quarter 2026 earnings release (Form 8-K, Exhibit 99.1), Intuitive Surgical, Inc. (SEC EDGAR), Oct 20, 2026
- S9Second quarter 2026 earnings release (Form 8-K, Exhibit 99.1), Intuitive Surgical, Inc. (SEC EDGAR), Jul 16, 2026
- S10First quarter 2026 earnings release (Form 8-K, Exhibit 99.1), Intuitive Surgical, Inc. (SEC EDGAR), Apr 21, 2026
- S11Fourth quarter and full year 2025 earnings release (Form 8-K, Exhibit 99.1), Intuitive Surgical, Inc. (SEC EDGAR), Jan 22, 2026
- S12Third quarter 2025 earnings release (Form 8-K, Exhibit 99.1), Intuitive Surgical, Inc. (SEC EDGAR), Oct 21, 2025
- S16Definitive proxy statement for the 2026 annual meeting (DEF 14A), Intuitive Surgical, Inc. (SEC EDGAR), Mar 13, 2026
- S19Form 8-K, Exhibit 99.1: completion of the acquisition of the ab medica, Abex and Excelencia Robotica distribution businesses, Intuitive Surgical, Inc. (SEC EDGAR), Mar 2, 2026
- S23Schedule 13G/A (Amendment No. 10), The Vanguard Group, common stock (event date Mar 13, 2026), The Vanguard Group (SEC EDGAR), Mar 27, 2026
- S24Schedule 13G, Vanguard Capital Management, common stock (event date Mar 31, 2026), Vanguard Capital Management (SEC EDGAR), Apr 30, 2026
- S26EDGAR filing index, Intuitive Surgical, Inc. (CIK 0001035267), U.S. Securities and Exchange Commission, Nov 6, 2026
Stryker
- S1Form 10-K for fiscal 2025 (year ended Dec 31, 2025), Stryker Corporation (SEC EDGAR), Feb 11, 2026
- S2Form 10-K for fiscal 2023 (year ended Dec 31, 2023), Stryker Corporation (SEC EDGAR), Feb 14, 2024
- S3Form 10-Q for Q3 2026 (quarter ended Sep 30, 2026), Stryker Corporation (SEC EDGAR), Oct 30, 2026
- S5Form 10-Q for Q1 2026 (quarter ended Mar 31, 2026), Stryker Corporation (SEC EDGAR), May 11, 2026
- S6Q4 and full-year 2024 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), Jan 28, 2025
- S7Q1 2025 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), May 1, 2025
- S8Q2 2025 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), Jul 31, 2025
- S9Q3 2025 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), Oct 30, 2025
- S10Q4 and full-year 2025 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), Jan 29, 2026
- S11Q1 2026 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), Apr 30, 2026
- S12Q2 2026 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), Jul 30, 2026
- S13Q3 2026 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), Oct 29, 2026
- S142026 proxy statement (DEF 14A), Stryker Corporation (SEC EDGAR), Mar 23, 2026
- S158-K (Item 8.01): recast of 2025 10-K items for the 2026 segment reorganization, Ex. 99.1, Stryker Corporation (SEC EDGAR), Jun 26, 2026
- S168-K (Item 8.01): cybersecurity incident identified Mar 11, 2026, Stryker Corporation (SEC EDGAR), Mar 11, 2026
- S178-K/A (Item 1.05): material cybersecurity incident, Stryker Corporation (SEC EDGAR), Apr 9, 2026
- S188-K (Item 7.01): cybersecurity incident update by the CISO, Stryker Corporation (SEC EDGAR), Mar 12, 2026
- S218-K (Item 2.01): completion of the Inari Medical acquisition, Stryker Corporation (SEC EDGAR), Feb 19, 2025
- S23Schedule 13G: Vanguard Capital Management LLC (event Mar 31, 2026), Vanguard Capital Management LLC (SEC EDGAR), Apr 30, 2026
- S298-K (Items 1.01, 2.03): $3.0 billion revolving credit agreement, Stryker Corporation (SEC EDGAR), Feb 27, 2025
- S31XBRL company facts: Stryker Corp (quarter-end debt split and cash), SEC (data.sec.gov), Nov 7, 2026
- S328-K (Item 7.01) Ex. 99.1: Unit 42 status letter on the cybersecurity incident, Stryker Corporation (SEC EDGAR), Mar 23, 2026
Disclaimer
For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.
Read the positions policyRead the full disclaimerHide the full disclaimer
Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.
All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.